Angiogenesis Inhibitors: all 4,430 studies that test it
Page 4 of 45. Open to participants first (542), then studies with results posted, then the rest; newest registration first within each.
- A Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherapy Followed by Immunotherapy-Based Systemic Therapy +/- L. Rhamnosus M9 for the First-Line Treatment of Advanced Digestive System Malignancies.RecruitingNCT06349044Not applicable
- Bortezomib, Pomalidomide, Dexamethasone for Systemic AL AmyloidosisRecruitingNCT06342466Phase 2
- Exploratory Study of Irinotecan Liposomes in Maintenance Therapy of Metastatic Colorectal CancerNot yet recruitingNCT06341309Phase 1/2
- Phase II Study of Irinotecan Liposomes in First-line Treatment of Metastatic Colorectal CancerRecruitingNCT06341296Phase 2
- Atezolizumab and Bevacizumab With Photon Radiotherapy for Unresectable Hepatocellular CarcinomaRecruitingNCT06339424Phase 2
- Precision Therapy for Solid Tumors: Synergistic CDK4/6 Inhibition and Anti-VEGF Targeting LncRNARecruitingNCT06307249Phase 1
- Endostar Combined With SBRT and Envafolimab in the Treatment of Advanced Gastrointestinal TumorsRecruitingNCT06301828Phase 2
- A Study of Valemetostat Tosylate (DS-3201b) With Atezolizumab and Bevacizumab in HCCRecruitingNCT06294548Phase 1/2
- TAS-102 Combined With Bevacizumab for Second-line Maintenance Treatment of Advanced Colorectal CancerRecruitingNCT06293014Phase 2
- Xanthohumol and Viral Infections (XL)RecruitingNCT06286657Not applicable
- Hop Compounds on the Immune System (VH)RecruitingNCT06286644Not applicable
- Modified TOMOX-HAIC in Combination With Sintilimab and Bevacizumab Biosimilar for First-line Treatment of Advanced Hepatocellular CarcinomaRecruitingNCT06285019Phase 2
- Efficacy and Safety of Chemotherapy With XELOX (Oxaliplatin + Capecitabine) and Bevacizumab in Combination With Adebrelimab in First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal CancerRecruitingNCT06282445Phase 2
- Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC PatientsRecruitingNCT06280495Phase 2/3
- Recombinant Human Endostatin Combined With Envafolimab and Synchronal RadiochemotherapyNot yet recruitingNCT06279754Phase 2
- Thalidomide Enhances Clinical Efficacy of Cetuximab Combined With Standard Chemotherapy for Left Colorectal CancerRecruitingNCT06279351Phase 2
- A Study of Camrelizumab Combined With Chemotherapy ± Thalidomide in First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)Not yet recruitingNCT06276933Phase 4
- DZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29)RecruitingNCT06276283Phase 2
- The Therapeutic Effect of Thalidomide in SyringomyeliaRecruitingNCT06268093Phase 2
- Efficacy and Safety of Anti-angiogenic Therapy With IV Bevacizumab in Patients With Symptomatic Cerebral Arteriovenous MalformationsRecruitingNCT06264531Phase 2/3
- Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal CancerRecruitingNCT06245356Phase 2
- Study of ZG005 in Combination With Paclitaxel＋Platinum-based ± Bevacizumab in Patients With Advanced Cervical CarcinomaRecruitingNCT06241235Phase 1/2
- Optimizing Reversal of HIV Latency With Combination TherapyNot yet recruitingNCT06240520Phase 1/2
- A Study Evaluating the Efficacy and Safety of ZG005 in Combination With Donafenib or Bevacizumab in Patients With Advanced Hepatocellular CarcinomaNot yet recruitingNCT06233994Not applicable
- Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP)RecruitingNCT06231680Phase 2
- Dose Escalation and Expansion Clinical Trial of Irinotecan Liposome Combined With Oxaliplatin and 5-FU/LV Plus Bevacizumab as First-line Treatment of Metastatic Colorectal CancerRecruitingNCT06225622Phase 1
- Xanthohumol as an Adjuvant in the Treatment of Septic ShockRecruitingNCT06225258Phase 2
- Cadonilimab in Combination With Bevacizumab and FOLFOX Regimen for the First-Line Treatment of Advanced Unresectable MSS-Type, RAS-Mutated Metastatic Colorectal CancerRecruitingNCT06218810Phase 2
- SHR-A1921 Combined With Bevacizumab in Triple-negative Breast Cancer With Brain MetastasesNot yet recruitingNCT06210438Phase 2
- Pilot Study Using Changes in Serum BCMA to Determine Disease Progression in Multiple MyelomaRecruitingNCT06209606Early Phase 1
- Liposomal Irinotecan and Capecitabine Plus Bevacizumab as Second-line Therapy in Metastatic Colorectal CancerNot yet recruitingNCT06192680Phase 2
- Pre-operative Vabysmo in Patients With Non-clearing Vitreous Hemorrhage Secondary to Proliferative Diabetic RetinopathyEnrolling by invitationNCT06191094Phase 4
- Phase 2 Study Applying MRD Techniques for Participants With Previously Untreated Multiple Myeloma Treated With D-VRd Prior To and After High-dose Therapy Followed by ASCT - TAURUSRecruitingNCT06189833Phase 2
- FeAsiBility of a Treatment Free Interval in Newly Diagnosed MM Patients Treated With Daratumumab-lenalidomide-dexamethasone (HOVON174MM)RecruitingNCT06187441Phase 3
- Liposomal Irinotecan and Leucovorin/5-fluorouracil Plus Bevacizumab in Metastatic Colorectal CancerRecruitingNCT06184698Phase 2
- MCLENA-2: A Phase II Clinical Trial for the Assessment of Lenalidomide in Patients With Mild Cognitive ImpairmentNot yet recruitingNCT06177028Phase 2
- Pola-R2 in Newly Diagnosed Non-fit Elderly DLBCL PatientsRecruitingNCT06176729Phase 2
- Bevacizumab and ICIs + hSRT in Symptomatic Melanoma Brain MetastasesRecruitingNCT06163820Phase 1/2
- A Randomized Phase II Study of LAZE rtiNib Alone Versus Lazertinib Plus bevaCizumab for NSCLC With EGFR + & SmokerRecruitingNCT06156527Phase 2
- Pyrotinib Combined With Capecitabine and Bevacizumab for Patients With HER2 Positive Breast Cancer and Brain MetastasesRecruitingNCT06152822Phase 2
- A Study of Tetrathiomolybdate (TM) Plus CapecitabineRecruitingNCT06134375Phase 1/2
- Atezolizumab and Bevacizumab With Proton Radiotherapy for Unresectable Hepatocellular CarcinomaRecruitingNCT06133062Phase 2
- The Efficacy and Safety of Utidelone Plus Tirelizumab and Bevacizumab for Advanced or Metastatic Triple-negative Breast Cancer (UTILIZABLE) ：Single-arm, Prospective, Open Clinical StudyRecruitingNCT06125080Phase 2
- BAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical CancerRecruitingNCT06123884Phase 2/3
- Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal MelanomaRecruitingNCT06121180Phase 2
- Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM)RecruitingNCT06087653Phase 1/2
- Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline TherapyRecruitingNCT06083844Phase 2
- First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian CancerNot yet recruitingNCT06063070Phase 2
- Envafolimab Combined With Trifluridine/Tipiracil and Bevacizumab in the Treatment of Refractory mCRC.RecruitingNCT06060704Phase 2
- A Pilot Bioequivalence Study of PomalidomideNot yet recruitingNCT06058689Phase 1
- A Clinical Study of Recombinant Human Vascular Endothelial Inhibitor in Combination With PRaG for Advanced Refractory Non-small Cell Lung CancerRecruitingNCT06047860Phase 2
- Treatment of Low Locally Advanced Rectal Cancer With Radiotherapy Removal TNT Plus Neoadjuvant TherapyNot yet recruitingNCT06035133Not applicable
- Multimodal Recurrence Scoring System for Stratifying Stage III Clear Cell Renal Cell Carcinoma of Receiving Adjuvant TreatmentNot yet recruitingNCT06032728Not applicable
- Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)RecruitingNCT06031688Phase 2
- Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological ImmunotherapieRecruitingNCT06031233Phase 4
- A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study)RecruitingNCT06023862Phase 2
- Thalidomide to Chemotherapy Related Nausea and Vomiting in Pancreatic CancerRecruitingNCT06017284Phase 3
- Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell LymphomaRecruitingNCT06015880Phase 1
- Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone LymphomaRecruitingNCT06006117Phase 3
- Efficacy and Safety of Lenalidomide Combined With Azacitidine vs Azacitidine in the Treatment of MDS-RSNot yet recruitingNCT06004765Phase 4
- Intraperitoneal Irinotecan With Concomitant FOLFOX and BevacizumabRecruitingNCT06003998Phase 2
- A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With CancerRecruitingNCT05999994Phase 2
- A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular CarcinomaNot yet recruitingNCT05976568Phase 2/3
- Hepatic Artery Infusion of Adebrelimab Combined With Bevacizumab in the Treatment of Advanced Hepatocellular Carcinoma With Failure of Systemic Therapy Combined With Interventional TherapyNot yet recruitingNCT05975463Phase 2
- XELOX +Bev +Tislelizumab for First-line Treatment of MSS/pMMR RAS-mutated mCRCRecruitingNCT05970302Phase 2
- OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older AdultsNot yet recruitingNCT05949424Phase 4
- Study of Cadonilimab Combined With Bevacizumab and Standard Chemotherapy as First Line Therapy in Unresectable Pleural MesotheliomaRecruitingNCT05930665Phase 2
- Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer .RecruitingNCT05927857Phase 1/2
- Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple MyelomaRecruitingNCT05922501Phase 2
- Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell LymphomaRecruitingNCT05910801Phase 2
- Endostar Plus Toripalimab as Adjuvant Therapy for Resectable Stage III-Oligometastatic Stage IV Cutaneous MelanomaRecruitingNCT05907512Phase 2
- KD6001 in Combination With Anti-PD-1 Antibody±Bevacizumab in Patients With Advanced HCC and Other Solid TumorsNot yet recruitingNCT05906524Phase 1/2
- A Phase II Stydy of Bevacizumab Plus Erlotinib in Patients for Krebs Cycle Altered CancerRecruitingNCT05904457Phase 2
- T-Dxd in Combination With Ramucirumab as HER2 Low Gastric or Gastroesophageal Junction (GEJ) AdenocarcinomaRecruitingNCT05894824Phase 1/2
- HAIC Plus A+T for Patients With High-risk HCC: a Single-arm Phase 2 TrialRecruitingNCT05886465Phase 2
- Efficacy and Safety of RC28-E Versus Aflibercept in Diabetic Macular EdemaRecruitingNCT05885503Phase 3
- TACE Combined With Bevacizumab in HCC (BCLC-B) Beyond Up-To-Seven CriteriaNot yet recruitingNCT05883176Phase 2
- Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell LymphomaRecruitingNCT05861050Phase 1/2
- Cadonilimab in Combination With Ramucirumab for the Treatment of Advanced Hepatocellular Carcinoma That Has Failed at Systemic TherapyRecruitingNCT05856864Phase 1
- Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal CancerRecruitingNCT05854498Phase 2
- Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapyRecruitingNCT05848765Phase 2
- Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Marginal Zone LymphomaRecruitingNCT05846750Phase 2
- Intravitreal Faricimab Injections or Fluocinolone Acetonide (0.19 mg) Intravitreal Implants vs Observation for Prevention of VA Loss Due to Radiation RetinopathyRecruitingNCT05844982Phase 3
- Sequential or Up-front Triple Treatment With Durvalumab, Tremelimumab and Bevacizumab for Non-resectable Hepatocellular Carcinoma (HCC) PatientsRecruitingNCT05844046Phase 2
- Lenalidomide to Reverse Drug Resistance After First-line Treatment of Advanced HCCNot yet recruitingNCT05831969Phase 2
- Efficacy and Safety of SCAI of Bevacizumab Combined With IC of Tislelizumab in the Treatment of Recurrent Glioblastoma.Not yet recruitingNCT05811793Not applicable
- Pro-miniCHOP-like Regimen for Treatment-naive Elderly PatientsRecruitingNCT05809180Not applicable
- Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal CancerRecruitingNCT05806931Phase 2
- QL1706 Monotherapy or in Combination With Bevacizumab and XELOX as First-line Treatment of Unresectable Advanced or Metastatic CRCRecruitingNCT05799820Phase 2
- Adjuvant Chemotherapy Combined With Targeted Therapy or Not in the T3-4N2 Colorectal Cancer PatientsRecruitingNCT05797467Phase 3
- A Phase Ⅰb/Ⅱ Clinical Study of SHR-A1811 Combined With Other Therapies in Patients With HER2 Low Advanced or Metastatic Breast Cancer.Not yet recruitingNCT05792410Phase 1/2
- Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple MyelomaRecruitingNCT05789303Phase 2
- Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma PatientsRecruitingNCT05776979Phase 2
- A Clinical Study of Injectable IMM0306 in Combination With LenalidomideNot yet recruitingNCT05771883Phase 1/2
- FUSCC Refractory TNBC Platform Study (FUTURE2.0)RecruitingNCT05749588Phase 2
- Efficacy and Safety of RC28-E Versus AfliberceptRecruitingNCT05727397Phase 3
- Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple MyelomaRecruitingNCT05722405Phase 4
- GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5RecruitingNCT05695508Phase 2
- Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine TumorsRecruitingNCT05687123Phase 1
- A Safety and Efficacy Study of Bevacizumab, Paclitaxel, Carboplatin Compared to Avastin® in Non-Small Cell Lung CancerRecruitingNCT05654454Phase 3